In oversight inquiry, key Democrat seeking 10 years’ worth of pricing, sales, research data from drug companies
SCOOP: As part of his oversight inquiry into a dozen drug makers, Rep. Elijah Cummings is seeking a whole host of information, including 10 years worth of sales, revenue, pricing…
This story first appeared in D.C. Diagnosis, STAT’s weekly newsletter about the politics and policy of health and medicine, which relaunched today. Sign up here to receive it in your inbox.
Rep. Elijah Cummings, the Maryland Democrat chairing the House Oversight Committee, put the pharmaceutical industry on notice this week when he launched an investigation into the industry’s drug pricing tactics. Until now, we didn’t know much more than the names of the 12 companies he sent letters to. But I dug around for more information ahead of the committee’s first hearing on the issue, on Jan. 29. Here’s what I learned:
- STAT got the skinny on what’s in the letters, and it’s a lot. Representatives from two companies involved in the probe said he’s seeking 10 years worth of sales, revenue, pricing, rebate, discount, and commercialization data; research and development expenses; information on
